FDA Approves Cavhanza (nilotinib) Orally Disintegrating Tablets for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
RegulatoryapprovedCavhanzaPositive
AI Analysis
Summary
Cycle Pharmaceuticals announced FDA approval of Cavhanza (nilotinib) Orally Disintegrating Tablets for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. The new formulation is designed to improve solubility and is launching soon.
Outcome Details
FDA approval of Cavhanza (nilotinib) Orally Disintegrating Tablets formulation
Importance:8/10
Sentiment:
0.90
FDA approvaloncologyCMLformulationnilotinib
Read the original article
Published by Drugs.com New Drug Approvals on June 2, 2026 7:06 PM